Free Trial
→ A grave, grave error. (From Porter & Company) (Ad)
NASDAQ:ALZN

Alzamend Neuro 9/13/2023 Earnings Report

Alzamend Neuro logo
$5.44 +2.12 (+63.86%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$5.10 -0.34 (-6.25%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Alzamend Neuro EPS Results

Actual EPS
-$54.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Alzamend Neuro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alzamend Neuro Announcement Details

Quarter
Date
9/13/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Alzamend Neuro's next earnings date is estimated for Tuesday, July 29, 2025, based on past reporting schedules.

Conference Call Resources

Alzamend Neuro Earnings Headlines

Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled
May 29 at 4:39 PM | msn.com
Alzamend Neuro Stock Doubles After Dosing of First Patient in Clinical Trial
May 29 at 11:38 AM | marketwatch.com
Buffett’s Next Move Could Shock Wall Street
In just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next great gold rush. Savvy insiders are quietly positioning now… before Buffett makes it official. Garrett Goggin has already pinpointed four tiny-gold-miners that could 100X once the announcement hits. It’s the perfect moment to be greedy — before the herd wakes up.
May 30, 2025 | Golden Portfolio (Ad)
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 29 at 8:00 AM | globenewswire.com
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 19, 2025 | globenewswire.com
Alzamend Neuro, Inc.: Alzamend Neuro Announces Reverse Stock Split
May 16, 2025 | finanznachrichten.de
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

View Alzamend Neuro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles